The Rotenone model of Parkinsonism - The five years inspection

Journal of Neural Transmission, Supplement

Volumn , Issue 70, 2006, Pages 269-272

  Hoglinger G U ^a,b   Oertel, W H ^b   Hirsch, E C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ROTENONE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; LOCOMOTION; MOTOR DYSFUNCTION; MUSCLE ATROPHY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PUBLICATION; RAT; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MOVEMENT; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE, SECONDARY; ROTENONE; SUBSTANTIA NIGRA; TAU PROTEINS; UNCOUPLING AGENTS;

EID: 33750289169     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306
2. Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of Rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753: 157-162
3. Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF (2004) Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187: 418-429
4. Garcia-Garcia F, Ponce S, Brown R, Cussen V, Krueger JM (2005) Sleep disturbances in the rotenone animal model of Parkinson disease. Brain Res 1042: 160-168
5. Höglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84: 491-502
6. Höglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95: 930-939
7. Kingsbury AE, Cooper M, Schapira AH, Foster OJ (2001) Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study. Ann Neurol 50: 142-149
8. Lapointe N, St-Hilaire M, Martinoli MG, Blanchet J, Gould P, Rouillard C, Cicchetti F (2004) Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18: 717-719
9. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145
10. Sherer TB, Kim JH, Betarbet R, Greenamyre JT (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179: 9-16
11. Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF (2004) Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 478: 418-426